EMEA-001822-PIP01-15-M01

Key facts

Invented name
Vosevi
Active substance
  • Sofosbuvir
  • velpatasvir
  • voxilaprevi
Therapeutic area
Infectious diseases
Decision number
P/0006/2020
PIP number
EMEA-001822-PIP01-15-M01
Pharmaceutical form(s)
  • Film-coated tablet
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of chronic hepatitis C
Route(s) of administration
Oral use
Contact for public enquiries
Gilead Sciences Ireland UC

E-mail: regulatory.pip@gilead.com
Tel. +44 1223897300

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating